What Happened?
Shares of medical technology company iRhythm Technologies (NASDAQ:IRTC) jumped 2% in the afternoon session after the company reported strong second-quarter financial results that surpassed expectations and raised its full-year guidance.
The cardiac monitoring company posted revenue of $224.2 million, a 20.1% increase from the previous year, which topped Wall Street's estimates. Earnings per share came in at $0.58, also significantly beating consensus estimates of $0.00. Following the strong performance, iRhythm slightly lifted its revenue guidance for the full year to $885 million at the midpoint. Overall, it was a solid quarter for the company, highlighted by beats on both the top and bottom lines.
After the initial pop, the shares cooled down to $130.03, up 1.5% from the previous close.
Is now the time to buy iRhythm? Access our full analysis report here, it’s free.
What Is The Market Telling Us
iRhythm’s shares are quite volatile and have had 19 moves greater than 5% over the last year. In that context, today’s move indicates the market considers this news meaningful but not something that would fundamentally change its perception of the business.
The biggest move we wrote about over the last year was 6 months ago when the stock dropped 7.1% on the news that the Trump administration's announcement of new global tariffs reignited trade policy uncertainty. The move came swiftly after the Supreme Court ruled the previous week that the president could not use the International Emergency Economic Powers Act (IEEPA) for such duties, a decision that had initially sent markets higher. However, the administration invoked a different authority, the Trade Act of 1974, to impose a 15% global tariff for up to 150 days. The rapid reimposition of trade barriers creates significant uncertainty for companies across multiple sectors that depend on international supply chains and global trade. Investors are now weighing the potential impact of these new duties on corporate earnings and broader economic activity.
iRhythm is down 25.8% since the beginning of the year, and at $130.03 per share, it is trading 31.3% below its 52-week high of $189.25 from January 2026. Despite the year-to-date decline, investors who bought $1,000 worth of iRhythm’s shares 5 years ago would now be looking at an investment worth $2,624.
WHILE YOU’RE HERE: The Next Palantir? One satellite company captures images of every point on Earth. Every single day. The Pentagon wants it. Hedge funds are using it to beat earnings. You’ve probably never heard of it.
This is what the early days of Palantir looked like before it became a giant. Same playbook. Different technology. If you missed Palantir, you need to see this. Claim The Stock Ticker for Free HERE.